ILLUMINA

ILLUMINA is a global leader in the life sciences industry, specializing in sequencing- and array-based solutions for genetic and genomic analysis. Founded in 1998, the company provides a comprehensive portfolio of instruments and consumables, including reagents, flow cells, and library preparation kits. Their technology supports whole-genome sequencing, genotyping, and noninvasive prenatal testing, alongside the Galleri multi-cancer early detection test. By serving genomic research centers, academic institutions, and biotechnology firms, ILLUMINA accelerates advancements in precision health and molecular diagnostics.

Operating with 5,000-10,000 employees across 25 global locations, the company maintains a robust operational footprint. Learn about ILLUMINA's global headquarters for detailed geographic and facility information. Their infrastructure supports complex genomic data platforms and secure reporting software, enabling rapid adoption of next-generation sequencing (NGS) technologies. The firm’s commitment to innovation is evidenced by its development of blood-based detection for minimal residual disease and other post-diagnostic applications, ensuring it remains at the forefront of the rapidly evolving biotechnology sector.

Financially, ILLUMINA demonstrates significant market presence with annual revenue reaching $4.5B. Explore financial highlights to review detailed metrics and funding history. The company’s strategic focus on scaling genomic research and clinical applications positions it competitively against industry peers like Agilent Technologies and GE HealthCare. Meet ILLUMINA's team to learn more about the leadership driving these technological breakthroughs. Through direct sales and life-science distribution channels, the company continues to deliver high-value genomic data solutions to a diverse global customer base.